open access
Sodium-glucose co-transporter-2 (SGLT2) inhibitors: novel oral antidiabetic drugs
open access
Abstract
Introduction. Due to rising diabetes mellitus morbidity and inadequate glycemic control new therapeutic agents, targeting on different metabolic pathways, need to be developed.
Materials and methods. Gained renal glucose reuptake in patients with diabetes mellitus is one of the target.
Results. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are able to affect this mechanism. SGLT2 localized in proximal renal tube are responsible for reuptake of 90% of glucose from the urine.
Conclusions. Inhibition of this transporting system induces glucosuria and decreases blood glucose level. Additionally SGLT2 inhibitors lead to body mass reduction and lower blood pressure. Most frequent adverse effects are genitourinary infections, particularly fungal. Long-term follow-up of patients with familial renal glucosuria (FRG), caused by genetic defect of SGLT2, has not revealed major abnormalities due to prolonged glucosuria.
Abstract
Introduction. Due to rising diabetes mellitus morbidity and inadequate glycemic control new therapeutic agents, targeting on different metabolic pathways, need to be developed.
Materials and methods. Gained renal glucose reuptake in patients with diabetes mellitus is one of the target.
Results. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are able to affect this mechanism. SGLT2 localized in proximal renal tube are responsible for reuptake of 90% of glucose from the urine.
Conclusions. Inhibition of this transporting system induces glucosuria and decreases blood glucose level. Additionally SGLT2 inhibitors lead to body mass reduction and lower blood pressure. Most frequent adverse effects are genitourinary infections, particularly fungal. Long-term follow-up of patients with familial renal glucosuria (FRG), caused by genetic defect of SGLT2, has not revealed major abnormalities due to prolonged glucosuria.
Keywords
sodium-glucose transporter 2, glycosuria, glycosuria renal, diabetes mellitus, type 2, hypoglycemic agents
About this articleTitle
Sodium-glucose co-transporter-2 (SGLT2) inhibitors: novel oral antidiabetic drugs
Journal
Issue
Article type
Review article
Pages
191-197
Published online
2013-10-25
Page views
2343
Article views/downloads
12493
DOI
10.5603/cd.36067
Bibliographic record
Diabetologia Kliniczna 2013;2(5):191-197.
Keywords
sodium-glucose transporter 2
glycosuria
glycosuria renal
diabetes mellitus
type 2
hypoglycemic agents
Authors
Błażej Przybysławski
Piotr Karbowiak
Jacek Rzeszotarski
Lech Walasek